Evidence-Based Guidance for Self-Administration of Injectable Contraception.
contraception
injections
medroxyprogesterone acetate
self administration
subcutaneous
Journal
Journal of midwifery & women's health
ISSN: 1542-2011
Titre abrégé: J Midwifery Womens Health
Pays: United States
ID NLM: 100909407
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
24
06
2020
revised:
13
10
2020
accepted:
22
10
2020
pubmed:
29
12
2020
medline:
29
12
2020
entrez:
28
12
2020
Statut:
ppublish
Résumé
The requirement of in-person visits every 3 months for a health care provider to administer intramuscular depot medroxyprogesterone acetate (DMPA-IM) is a significant barrier to its use, particularly in the wake of the coronavirus pandemic. Time and travel costs as well as scheduling conflicts also negatively impact the receipt of subsequent contraceptive injections, which can result in unintended pregnancies. Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) can be self-administered by individuals at home, expanding contraceptive access, convenience, and reproductive autonomy. With 30% less progestin, DMPA-SC improves upon the DMPA-IM formulation while retaining efficacy. As part of comprehensive contraceptive counseling, health care providers should consider offering DMPA-SC to eligible individuals interested in self-administration. Using a case study approach, evidence-based recommendations are reviewed for the off-label use of self-administered DMPA-SC in the United States.
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
108-112Commentaires et corrections
Type : CommentOn
Informations de copyright
© 2020 by the American College of Nurse-Midwives.
Références
Daniels K, Daugherty J, Jones J, Mosher W. Current contraceptive use and variation by selected characteristics among women aged 15-44: United States, 2011-2013. Natl Health Stat Report. 2015;10(86):1-14.
US Food & Drug Administration. Depo-SubQ Provera 104 (Medroxyprogesterone Acetate) injectable suspension, new drug application No.: 021583. Updated May 9, 2007. Accessed September 9, 2007. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021583s000TOC.cfm
Beasley A, White K O, Cremers S, Westhoff C. Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate. Contraception. 2014;89(5):352-356.
Lindberg LD. Early Impacts of the COVID-19 Pandemic: Findings from the 2020 Guttmacher Survey of Reproductive Health Experiences. Guttmacher Institute; 2020. Accessed Septmeber 28, 2020. https://www.guttmacher.org/report/early-impacts-covid-19-pandemic-findings-2020-guttmacher-survey-reproductive-health
Kaunitz A Long-acting injectable contraception with depot medroxyprogesterone acetate. Am J Obstet Gynecol. 1994;170(5 Pt 2):1543-1549.
Jain J, Dutton C, Nicosia A, Wajszczuk C, Bode FR, Mishell DR Jr. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Contraception. 2004;70(1):11-18.
Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception. 2004;70(4):269-275.
Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397-404.
Kennedy CE, Yeh PT, Gaffield ML, Brady M, Narasimhan M. Self-administration of injectable contraception: a systematic review and meta-analysis. BMJ Glob Health. 2019;4(2):e00135
Kohn JE, Simons HR, Della Badia L, et al. Increased 1-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood. Contraception. 2018;97(3):198-204.
Burke HM, Chen M, Buluzi M, et al. Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomized controlled trial. Lancet Glob Health. 2018;6(5):e568-e578.
Curtis KM, Tepper NK, Jatlaoui TC, et al. US medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(3):1-103.
Daniels K, Mosher WD. Contraceptive methods women have ever used: United States, 1982-2010. Natl Health Stat Report. 2013(62):1-15.
Westhoff C, Jain JK, Milsom I, Ray A. Changes in weight with depot medroxyprogesterone Acetate subcutaneous injection 104 mg/0.65 mL. Contraception. 2007;75(4):261-267.
Arias RD, Jain JK, Brucker C, et al. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. Contraception. 2006;74(3):234-238.
American College of Obstetricians and Gynecologists. Committee opinion no. 602: depot medroxyprogesterone acetate and bone effects. Obstet Gynecol. 2014;123(6):1398-1402.
Dragoman MV, Gaffield ME. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): a systematic review. Contraception. 2016;94(3):202-215.
Cover J, Namagembe A, Tumusiime J, Lim J, Drake JK, Mbonye AK. A prospective cohort study of the feasibility and acceptability of depot medroxyprogesterone acetate administered subcutaneously through self-injection. Contraception. 2017;95(3):306-311.
Cover J, Ba M, Lim J, Drake JK, Daff DM. Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study. Contraception. 2017;96(3):203-210.
Cameron ST, Glasier A, Johnstone A. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception. Contraception. 2012;85(5):458-464.
Upadhyay UD, Zlidar VM, Foster DG. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States. Contraception. 2016;94(4):303-313.
Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(4):1-66.
Frid A, Hirsch L, Gaspar R, et al. New injection recommendations for patients with diabetes. Diabetes Metab. 2010;36 Suppl 2:S3-18.
Yen PH, Leasure AR. Use and effectiveness of the teach-back method in patient education and health outcomes. Fed Pract. 2019;36(6):284-289.
Rittberg R, Dissanayake T, Katz SJ. A qualitative analysis of methotrexate self-injection education videos on YouTube. Clin Rheumatol. 2016;35(5):1329-1333.
Yen PH, Leasure AR. Use and effectiveness of the teach-back method in patient education and health outcomes. Fed Pract. 2019;36(6):284-289.